author-photo

Bruno Cenni

Novartis

7

Papers

166

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.

2021 Clinical and Translational Science
Show All
- Source
- Cite
- Save
Citations (2)
Design of Potent and Selective Covalent Inhibitorsof Bruton’s Tyrosine Kinase Targeting an Inactive Conformation

2019 ACS Medicinal Chemistry Letters
Show All
- Source
- Cite
- Save
Citations (5)
Endothelial Bmx tyrosine kinase activity is essential for myocardial hypertrophy and remodeling.

2015 Proceedings of the National Academy of Sciences of the United States of America
Show All
- Source
- Cite
- Save
Citations (16)
The Tyrosine Kinase BMX Is an Essential Mediator of Inflammatory Arthritis in a Kinase-Independent Manner

2011 Journal of Immunology
Show All
- Source
- Cite
- Save
Citations (25)
Evaluation of protease‐activated receptor 2 in murine models of arthritis

2007 Arthritis & Rheumatism
Show All
- Source
- Cite
- Save
Citations (57)